Lifestance Health (LFST)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
$13.43-5.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
QuarterlyIQ Insights · LFST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 15.3% |
| Our one-year growth estimate | diamond | 20.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 4.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 19 industry peers
LFST — officer change
Dated 2026-10-16
Director — Teresa DeLuca, M.D.: The filing discloses the resignation of a board director, which is a departure from the board but typically carries lower materiality than the departure of a C-suite executive.
Why it matters: LifeStance raised its 2026 revenue range after Q2 growth. Q3 results will show if that pace holds.
Supportive ifOn November 5, Q3 revenue is above $440 million, the top of the company’s range.
Worry ifOn November 5, Q3 revenue is below $420 million, the bottom of the company’s range.
Why it matters: Q2 Adjusted EBITDA nearly doubled from a year earlier. Q3 results will test if profit gains continue.
Supportive ifOn November 5, Q3 Adjusted EBITDA is above $59 million, the top of the company’s range.
Worry ifOn November 5, Q3 Adjusted EBITDA is below $49 million, the low end of the company’s range.
Why it matters: The board approved a new $100 million plan, but the filing says it does not require any share purchases.
Watch forA company filing or release reports shares bought under the new plan, with the number of shares and amount spent.
Also watch forThe next quarterly filing reports no shares bought under the new plan.
Why it matters: The health care sector is in a mature phase, with slowing growth. LifeStance’s Q3 report will show whether its growth differs.
Worry ifQ3 revenue growth is below 20% year over year, compared with Q2 growth of 26%.
Less concerning ifQ3 revenue growth is at least 26% year over year, matching or topping Q2 growth.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$142 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $343 loss on $10,000 · 3.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,706 loss on $10,000 · 17.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More clinicians and visits helped drive Q2 growth. A slowdown could weaken that source of revenue gains.
Watch forQ3 clinician count and visit volume both rise from Q2’s 8,542 clinicians and 2.6 million visits.
Also watch forQ3 clinician count or visit volume falls below Q2’s 8,542 clinicians or 2.6 million visits.